◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Biofrontera AG (B8FK) Financial History

Name: Biofrontera AG (B8FK) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-16

Biofrontera AG (B8FK) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Leverkusen, Germany with about 69 employees. Its market capitalization is roughly €15 million. In the fiscal year ended 2025-12-31, B8FK reported €13M in revenue and (€4M) in net income.

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally.

Interactive charts & full statements →

B8FK Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	€13M	€12M	€32M	€26M	—
Gross Profit	€11M	€10M	€26M	€21M	—
Operating Income (EBIT)	(€1M)	(€2M)	€5M	€2M	—
Net Income	(€4M)	(€4M)	(€0M)	(€44M)	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

B8FK Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-03-31	2024-12-31
Total Revenue	€4M	€1M	€4M	€3M	€11M
Gross Profit	€3M	€2M	€2M	€3M	€9M
Operating Income (EBIT)	€0M	(€1M)	(€1M)	(€0M)	(€0M)
Net Income	€2M	€0M	(€0M)	€1M	€2M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

B8FK Free Cash Flow History

B8FK Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	€21M	€30M	€31M	€33M	—
Total Liabilities	€6M	€11M	€11M	€12M	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive B8FK viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

AYTU · Aytu BioPharma, Inc. — $26 million
TXMD · TherapeuticsMD, Inc. — $24 million
AVCN · Avicanna Inc. — $17 million
BFRI · Biofrontera Inc. — $17 million
CABR · Caring Brands, Inc. — $13 million
INM · InMed Pharmaceuticals Inc. — $8 million
SNOA · Sonoma Pharmaceuticals, Inc. — $7 million
GELS · Gelteq Limited — $6 million

← B7E All “B” companies BA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.